Krischan J Hudson

2.1k total citations
17 papers, 698 citations indexed

About

Krischan J Hudson is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Krischan J Hudson has authored 17 papers receiving a total of 698 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 9 papers in Virology and 4 papers in Epidemiology. Recurrent topics in Krischan J Hudson's work include HIV/AIDS drug development and treatment (11 papers), HIV/AIDS Research and Interventions (10 papers) and HIV Research and Treatment (9 papers). Krischan J Hudson is often cited by papers focused on HIV/AIDS drug development and treatment (11 papers), HIV/AIDS Research and Interventions (10 papers) and HIV Research and Treatment (9 papers). Krischan J Hudson collaborates with scholars based in United States, United Kingdom and Belgium. Krischan J Hudson's co-authors include William Spreen, David A. Margolis, Susan L. Ford, Britt Stancil, Kimberly Y. Smith, Sandy Griffith, Parul Patel, Miranda Murray, Roberto A. Calle and Kenneth H. Mayer and has published in prestigious journals such as SHILAP Revista de lepidopterología, CHEST Journal and The Lancet Infectious Diseases.

In The Last Decade

Krischan J Hudson

17 papers receiving 686 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Krischan J Hudson United States	11	535	358	214	114	84	17	698
Maura Laverty United States	8	356 0.7×	243 0.7×	181 0.8×	53 0.5×	59 0.7×	15	517
Vadim Pokrovskiy Russia	6	754 1.4×	563 1.6×	146 0.7×	50 0.4×	296 3.5×	13	828
Steven G. Deeks United States	2	403 0.8×	331 0.9×	185 0.9×	45 0.4×	356 4.2×	2	636
Dan Duiculescu Romania	11	805 1.5×	628 1.8×	225 1.1×	92 0.8×	219 2.6×	22	949
Laurence Slama France	14	303 0.6×	247 0.7×	105 0.5×	90 0.8×	319 3.8×	35	623
Jemma L. O’Connor United Kingdom	8	273 0.5×	174 0.5×	131 0.6×	30 0.3×	216 2.6×	10	449
Roberta Gagliardini Italy	15	411 0.8×	281 0.8×	129 0.6×	41 0.4×	120 1.4×	65	544
Brandon Klein United States	9	356 0.7×	177 0.5×	157 0.7×	36 0.3×	32 0.4×	33	471
Fabienne Caby France	9	232 0.4×	231 0.6×	92 0.4×	24 0.2×	123 1.5×	26	365
J. L. Blanco Spain	12	451 0.8×	380 1.1×	139 0.6×	94 0.8×	198 2.4×	15	666

Countries citing papers authored by Krischan J Hudson

Since Specialization

Citations

This map shows the geographic impact of Krischan J Hudson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Krischan J Hudson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Krischan J Hudson more than expected).

Fields of papers citing papers by Krischan J Hudson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Krischan J Hudson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Krischan J Hudson. The network helps show where Krischan J Hudson may publish in the future.

Co-authorship network of co-authors of Krischan J Hudson

This figure shows the co-authorship network connecting the top 25 collaborators of Krischan J Hudson. A scholar is included among the top collaborators of Krischan J Hudson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Krischan J Hudson. Krischan J Hudson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Volkmann, Elizabeth R., Christopher P. Denton, Martin Kolb, et al.. (2024). Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis. European Respiratory Review. 33(172). 240015–240015. 6 indexed citations

Song, Yang, et al.. (2023). PHARMACOKINECTS STUDY TO EVALUATE DRUG-DRUG INTERACTIONS (DDI) BETWEEN HZN-825 AND PIRFENIDONE/NINTEDANIB. CHEST Journal. 164(4). A126–A127. 3 indexed citations

Chounta, Vasiliki, Edgar T. Overton, Anthony Mills, et al.. (2021). Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M). Patient. 14(6). 849–862. 47 indexed citations

Mantsios, Andrea, Miranda Murray, Tahilin Sanchez Karver, et al.. (2021). Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials. BMC Health Services Research. 21(1). 255–255. 34 indexed citations

Kerrigan, Deanna, Miranda Murray, Tahilin Sanchez Karver, et al.. (2020). Feasibility of Implementing Long-Acting Injectable Antiretroviral Therapy to Treat HIV: A Survey of Health Providers from the 13 Countries Participating in the ATLAS-2M Trial. AIDS Research and Human Retroviruses. 37(3). 207–213. 4 indexed citations

Murray, Miranda, Deanna Kerrigan, Krischan J Hudson, et al.. (2020). Identifying appropriate candidates for long-acting antiretroviral therapy: findings from a survey of health care providers in the ATLAS-2M trial. SHILAP Revista de lepidopterología. 21(4). 105–113. 10 indexed citations

Mantsios, Andrea, Miranda Murray, Tahilin Sanchez Karver, et al.. (2020). Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials. AIDS and Behavior. 24(12). 3473–3481. 35 indexed citations

Murray, Miranda, Antonio Antela, Anthony Mills, et al.. (2020). Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks. AIDS and Behavior. 24(12). 3533–3544. 53 indexed citations

Talarico, Christine L., Sterling Wu, Marty St. Clair, et al.. (2020). 1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome. Open Forum Infectious Diseases. 7(Supplement_1). S540–S541. 4 indexed citations

10.

D’Amico, Ronald, Paul Benn, Cynthia McCoig, et al.. (2020). LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials. Open Forum Infectious Diseases. 7(Supplement_1). S847–S848. 2 indexed citations

11.

Patel, Parul, Susan L. Ford, Herta Crauwels, et al.. (2019). 2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies. Open Forum Infectious Diseases. 6(Supplement_2). S865–S866. 17 indexed citations

12.

Cutrell, Amy, Ronald D’Amico, David Dorey, et al.. (2019). 884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies. Open Forum Infectious Diseases. 6(Supplement_2). S20–S20. 4 indexed citations

13.

Murray, Miranda, Martin Markowitz, Ian Frank, et al.. (2018). Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. HIV Clinical Trials. 19(4). 129–138. 54 indexed citations

14.

Markowitz, Martin, Ian Frank, Robert M. Grant, et al.. (2017). Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. The Lancet HIV. 4(8). e331–e340. 164 indexed citations

15.

Margolis, David A., Cynthia Brinson, Graham Smith, et al.. (2015). Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. The Lancet Infectious Diseases. 15(10). 1145–1155. 157 indexed citations

16.

Dong, Jennifer, Michelle I. Rossulek, Veena Somayaji, et al.. (2015). Pharmacokinetics and pharmacodynamics of PF‐05231023, a novel long‐acting FGF21 mimetic, in a first‐in‐human study. British Journal of Clinical Pharmacology. 80(5). 1051–1063. 85 indexed citations

17.

Gustavson, Stephanie M., Veena Somayaji, Krischan J Hudson, et al.. (2011). Effects of a long‐acting GLP‐1 mimetic (PF‐04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 13(11). 1056–1058. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact